Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Drugs for Cardiology/Vascular Diseases in Phase I Clinical Development

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    Country filter
      News Type filter
        Company filter
          Product Type filter
            Deal Size filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Cardior Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ARVO 2021

              Participation Not Confirmed

              Update your events

              Independent Peer-Reviewed Study Validates Therapeutic Mode of Action of Cardior's First-in-Class Heart Failure Program

              Contact the Supplier

              Lead Product(s): CDR132L

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: CDR132L

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 29, 2021

              Details:

              The recent peer-reviewed study confirms the therapeutic mode of action of Cardior´s lead program CDR132L. CDR132L blocks the naturally occurring microRNA miR-132 which, if overexpressed, is a key driver of heart failure.

              Arrowhead Pharmaceuticals

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ARVO 2021

              Participation Not Confirmed

              Update your events

              Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

              Contact the Supplier

              Lead Product(s): ARO-APOC3

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: ARO-APOC3

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 01, 2021

              Details:

              Following the FDA’s review of the IND, the company intends to initiate a Phase 2b dose-finding clinical study (ARO-APOC3-2001) in patients with severe hypertriglyceridemia (sHTG).

              Silence Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ARVO 2021

              Participation Not Confirmed

              Update your events

              Silence Therapeutics Initiates Dosing in Phase 1 Clinical Trial of SLN360 for Cardiovascular Disease Due to High Lipoprotein(a)

              Contact the Supplier

              Lead Product(s): SLN360

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: SLN360

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Medpace, Inc

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 17, 2021

              Details:

              This first-in-human study is investigating the safety, tolerability, pharmacokinetic and pharmacodynamic response of SLN360 in people with elevated Lp(a) levels approximately ≥60 mg/dL.

              Catalent Pharma Solutions

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED STATES United States

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              ARVO 2021

              Participation Not Confirmed

              Update your events

              Catalent Signs Development and Manufacturing Agreement with Trizell for Macrophage-based Advanced Cell Therapy

              Contact the Supplier

              Lead Product(s): Macrophage-based advanced cell therapy

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Trizell

              Deal Size: Undisclosed Upfront Cash: Undisclosed